Jennison Associates
TCRT icon

Jennison Associates’s Alaunos Therapeutics TCRT Stock Holding History

Jennison Associates’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-10,120
Closed -$4.01M – 756
2014
Q3 		$4.01M Buy
10,120
+15
+0.1% +$7.23K ﹤0.01% 515
2014
Q2 		$6.11M Sell
10,105
-1,146
-10% -$638K 0.01% 495
2014
Q1 		$7.73M Sell
11,251
-6,916
-38% -$4.63M 0.01% 501
2013
Q4 		$11.8M Buy
18,167
+12,944
+248% +$7.71M 0.01% 480
2013
Q3 		$3.09M Buy
+5,223
New +$2.35M ﹤0.01% 537

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jennison Associates's TCRT Position: Q4 2014 in Review

Jennison Associates sold out of Alaunos Therapeutics (TCRT) in Q4 2014, closing a stake of 10,120 shares — an estimated $4.01M sold.

Jennison Associates first reported a position in TCRT in Q3 2013 and held it in 5 quarters. The position peaked at $11.8M in Q4 2013. 85 funds tracked by Wall St. Rank hold TCRT as of Q4 2014.

  • Jennison Associates reported no remaining Alaunos Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Jennison Associates sold 10,120 Alaunos Therapeutics shares in Q4 2014, an estimated $4.01M.
  • Jennison Associates first reported a position in Alaunos Therapeutics in Q3 2013 and held it in 5 quarters.
  • Jennison Associates's Alaunos Therapeutics position peaked at $11.8M in Q4 2013.
  • 85 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2014.

Based on Jennison Associates's 13F filing for Q4 2014, filed 6 Feb 2015.